EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience



Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience



Journal of Neuro-Oncology 139(1): 107-116



Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically excluded patients with PMBT due to the poor prognosis, concomitant drug interactions and concerns regarding toxicities. Retrospective data were collected on clinical and tumour characteristics of patients referred for consideration of Ph1 trials in the Royal Marsden Hospital between June 2004 and August 2016. Survival analyses were performed using the Kaplan-Meier method, Cox proportional hazards model. Chi squared test was used to measure bivariate associations between categorical variables. 100pts with advanced PMBT were referred. At initial consultation, patients had a median ECOG PS 1, median age 48 years (range 18-70); 69% were men, 76% had glioblastoma; 68% were on AEDs, 63% required steroid therapy; median number of prior treatments was two. Median OS for patients treated on a Ph1 trials was 9.3 months (95% CI 5.9-12.9) versus 5.3 months (95% CI 4.1-6.1) for patients that did not proceed with a Ph1 trial, p = 0.0094. Steroid use, poor PS, neutrophil-to-lymphocyte ratio and treatment on a Ph1 trial were shown to independently influence OS. We report a survival benefit for patients with PMBT treated on Ph1 trials. Toxicity and efficacy outcomes were comparable to the general Ph1 population. In the absence of an internationally recognized standard second line treatment for patients with recurrent PMBT, more Ph1 trials should allow enrolment of patients with refractory PMBT and Ph1 trial participation should be considered at an earlier stage.

(PDF emailed within 0-6 h: $19.90)

Accession: 065494577

Download citation: RISBibTeXText

PMID: 29637509

DOI: 10.1007/s11060-018-2847-z



Related references

Radiosurgery/stereotactic external beam radiotherapy for malignant brain tumours: the Royal Marsden Hospital experience. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 135: 91-104, 1994

Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience. Seminars in Hematology 38(3): 209-218, 2001

Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. Journal of Pediatric Hematology/Oncology 36(3): 218-223, 2014

An analysis of the results of initial treatment for patients with malignant tumours of the thyroid seen at the Royal Marsden Hospital, 1945-1963. Neoplastic Disease at Various Sites 6: 276-290, 1970

Cervical node metastasis of unknown primary site The Royal Marsden Hospital 15 year experience. British Journal of Cancer 78(SUPPL 2): 6, 1998

Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer Research 35(12): 6713-6722, 2016

A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Research 34(7): 3663-3668, 2014

Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 118(5): 1422-1428, 2012

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leukemia & Lymphoma 58(2): 494-497, 2016

Clinical outcome and prognostic factors for patients treated within the context of a phase I study the Royal Marsden Hospital experience. British Journal of Cancer 98(6): 1029-1033, 2008

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clinical Sarcoma Research 5(): 5-5, 2015

Paediatric tumours in the adult population: the experience of the Royal Marsden Hospital 1974-1990. Medical and Pediatric Oncology 26(3): 153-159, 1996

Erythroleukemia 18 year experience from the Royal Marsden Hospital. Blood 90(10 SUPPL 1 PART 2): 243B, Nov 15, 1997

Trends in survival of patients diagnosed with primary Testicular tumours in Leicestershire A 15-year experience. British Journal of Cancer 86(Supplement 1): S65, June, 2002

Biphenotypic leukemia Eight year experience from the Royal Marsden Hospital. Blood 90(10 SUPPL 1 PART 2): 243B, Nov 15, 1997